Administration of siponimod in real clinical practice in Russia

Introduction. The study was driven by the prevalence of secondary progressive multiple sclerosis (SPMS) in Russia and the lack of data on siponimod in the real clinical practice (RCP).

Aim. To collect and analyze data on the administration of siponimod in SPMS patients within Russia’s RCP as part of the EMBOSSES study (rEtrospective Multicenter oBservatiOnal Study Siponimod rEal-world Spms).

Materials and methods. The study encompassed data of 606 SPMS patients from 11 centers who received siponimod for at least 6 months. The analysed data included demographic and clinical characteristics of patients, changes in the Expanded Disability Status Scale (EDSS) scores over time, percentage of patients with 6-month confirmed disability progression (6mCDP), annualized relapse rate (ARR) for MS, radiological signs of the disease activity and adverse events (AEs).

Results. Among the study patients, women predominated (64.9%), while men accounted for 35.1%. The median age of patients was 49.5 (±8.9) years. 143 (23.6%) patients reported relapses during 2 years, whereas relapse-free SPMS was observed in 463 (76.4%) patients. The average EDSS scores remained stable, demonstrating minimal changes from 5.44 (±0.998) to 5.58 (±1.028) scores during the 2-year therapy. The percentage of patients free from 6mCDP was 85.5%. The KaplanMeier analysis revealed that 25% of patients achieved 6mCDP by Month 27 of therapy. The average ARR decreased from 0.14 to 0.032 at 12 months and remained low (0.062) after 2 years of treatment. The MRI showed a decrease in the percentage of patients with Gd+ T1 lesions to their complete absence over 2 years of therapy. Main AEs: lymphopenia, bradycardia, and elevated liver enzymes; serious AEs were observed in 3.3% of all cases.

Conclusions. Siponimod demonstrated efficacy in controlling disability progression and inflammatory activity, as well as a favourable safety profile in patients with SPMS in the RCP setting. The results confirm the feasibility of using siponimod in patients with SPMS.

1. Хачанова НВ, Евдошенко ЕП, Скоромец АА, Пронин ИН, Гузева ВИ, Алифирова ВМ и др. Рассеянный склероз: клинические рекомендации. М.; 2022. 121 с. Режим доступа: http://disuria.ru/_ld/12/1226_kr22G35p0MZ.pdf.

2. Hauser S, Cree B. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1380–1390. https://doi.org/10.1016/j.amjmed.2020.05.049.

3. Boĭko AN, Gusev EI. Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(2-2):92–106. (In Russ.) https://doi.org/10.17116/jnevro20171172292-106.

4. Ignatyeva VI, Derkach EV. Secondary progressive multiple sclerosis: number of patients and public drug supply in Russia. Medical Technologies. Assessment and Choice. 2021;43(2):38–43. (In Russ.) https://doi.org/10.17116/medtech20214302138.

5. Caseby SCL, Woodhouse FA, Montgomery SM, Kroes MA, Duddy ME. Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey. Health Sci Rep. 2022;5(1):e474. https://doi.org/10.1002/hsr2.474.

6. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286. https://doi.org/10.1212/WNL.0000000000000560.

7. Ziemssen T, Bhan V, Chataway J, Chitnis T, Cree BAC, Havrdova EK et al. Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200064. https://doi.org/10.1212/NXI.0000000000200064.

8. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788–1795. https://doi.org/10.1212/01.wnl.0000146958.77317.3e.

9. Wiendl H, Meuth SG. Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. Drugs. 2015;75(9):947–977. https://doi.org/10.1007/s40265-015-0411-0.

10. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17(5):405–415. https://doi.org/10.1016/S1474-4422(18)30069-3.

11. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263–1273. https://doi.org/10.1016/S0140-6736(18)30475-6.

12. Cree BAC, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH et al. Longterm efficacy and safety of siponimod in patients with secondary progres-sive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years. Mult Scler. 2022;28(10):1591–1605. https://doi.org/10.1177/13524585221083194.

13. Krasnov VS, Kolontareva YuM. Siponimod: a new view at the therapy of secondary progressive multiple sclerosis. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(7):124–129. (In Russ.) https://doi.org/10.17116/jnevro2021121071124.

14. Korobko DS, Arkhipov IE, Prokaeva AI, Tretyakova EV. The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report. Consilium Medicum. 2023;25(2):95–100. (In Russ.) https://doi.org/10.26442/20751753.2023.2.202229.

15. Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2–10. https://doi.org/10.1002/pds.3891.

16. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PloS Med. 2007;4(10):e297. https://doi.org/10.1371/journal.pmed.0040297.

17. Stepanova AD, Evdoshenko EP, Shumilina MV, Korobko DS, Barabanova MA, Abroskinа MV et al. Validation of Russian-language version of the Expanded Disability Status Scale (EDSS) for patients with multiple sclerosis in the Russian Federation. Medical Technologies. Assessment and Choice. 2023;45(1):41–49. (In Russ.) https://doi.org/10.17116/medtech20234501141.

18. Tornio A, Backman JT. Cytochrome P450 in Pharmacogenetics: An Update. Adv Pharmacol. 2018;83:3–32. https://doi.org/10.1016/bs.apha.2018.04.007.

19. Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM et al. Clinical PharmacogeneticsImplementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302–309. https://doi.org/10.1002/ cpt.2008.

20. Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA et al. SLCO1B1 gene-polymorphismfrequencyin Russian and Nanaipopulations. Pharmgenomics Pers Med. 2017;10:93–99. https://doi.org/10.2147/PGPM.S129665.

21. Díaz-Villamarín X, Pinar-Morales R, Barrero-Hernandez FJ, Antúnez-Rodríguez A, Cabeza-Barrera J, Moron-Romero R. Pharmacogenetics of siponimod: A systematic review. Biomed Pharmacother. 2022;153:113536. https://doi.org/10.1016/j.biopha.2022.113536.

22. Evdoshenko EP, Neofidof NA, Bakhtiiarova KZ, Davydovskaya MV, Kairbekova EI, Kolontareva YuM et al. The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(10-2): 110-119. (In Russ.) https://doi.org/10.17116/jnevro2019119102110.

23. Tremlett H, Zhao Y, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14(3):314–324. https://doi.org/10.1177/1352458507084264.

24. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20);1430–1438. https://doi.org/10.1056/NEJM200011163432001.

25. Ebers GC. The natural history of multiple sclerosis. Neurol Sci. 2000;21(4):815–817. https://doi.org/10.1007/s100720070018.

26. Sriwastava S, Kataria S, Srivastava S, Kazemlou S, Gao S, Wen S et al. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2021;360:577721. https://doi.org/10.1016/j.jneuroim.2021.577721.

27. Regner-Nelke L, Pawlitzki M, WillisonA, Rolfes L, Oezalp S, Nelke C et al. Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis. Neurol Res Pract. 2022;4(1):55. https://doi.org/10.1186/s42466-022-00219-3.